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Background: Competing health concerns present real obstacles to people living with diabetes and other chronic
diseases as well as to their primary care providers. Guideline implementation interventions rarely acknowledge this,
leaving both patients and providers feeling overwhelmed by the volume of recommended actions. Interprofessional
(IP) shared decision-making (SDM) with the use of decision aids may help to set treatment priorities. We developed an
evidence-based SDM intervention for patients with diabetes and other conditions that was framed by the IP-SDM
model and followed a user-centered approach. Our objective in the present study is to pilot an IP-SDM and goal-
setting toolkit following the Knowledge-to-Action Framework to assess (1) intervention fidelity and the feasibility of
conducting a larger trial and (2) impact on decisional conflict, diabetes distress, health-related quality of life and patient
assessment of chronic illness care.
Methods/Design: A two-step, parallel-group, clustered randomized controlled trial (RCT) will be conducted, with
the primary goal being to assess intervention fidelity and the feasibility of conducting a larger RCT. The first step
is a provider-directed implementation only; the second (after a 6-month delay) involves both provider- and
patient-directed implementation. Half of the clusters will be assigned to receive the IP-SDM toolkit, and the other
will be assigned to be mailed a diabetes guidelines summary. Individual interviews with patients, their family
members and health care providers will be conducted upon trial completion to explore toolkit use. A secondary
purpose of this trial is to gather estimates of the toolkit’s impact on decisional conflict. Secondary outcomes
include diabetes distress, quality of life and chronic illness care, which will be assessed on the basis of patient-
completed questionnaires of validated scales at baseline and at 6 and 12 months. Multilevel hierarchical regression
models will be used to account for the clustered nature of the data.
Discussion: An individualized approach to patients with multiple chronic conditions using SDM and goal setting is a
desirable strategy for achieving guideline-concordant treatment in a patient-centered fashion. Our pilot trial will provide
insights regarding strategies for the routine implementation of such interventions in clinical practice, and it will offer an
assessment of the impact of this approach.
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Competing patient and physician priorities and compet-
ing disease priorities present challenges in the provision
of care for individuals with complex medical needs and
multiple comorbidities [1]. Shared decision-making (SDM)
tools, or decision aids, can be used to help prioritize treat-
ment options and have the potential to improve patient
care. The authors of a systematic review of randomized
controlled trials (RCTs) of SDM identified 11 studies [2], 2
of which examined long-term decisions that occurred over
multiple sessions in a 9- and 12-month time frame and
reported improved adherence, reduced depression and
improved well-being.
Despite the potential for SDM to improve patient-
centered outcomes, implementation of SDM in care has
been limited because of clinician factors (such as limited
time, lack of applicability to the patient situation [3]) and
patient factors (such as patient–provider power imbalance,
health literacy and denial about the condition [4]). How-
ever, facilitators of SDM include provider motivation to en-
gage in SDM, the perception of having a positive impact
on the clinical process and outcome [5], health care pro-
vider training, patient-mediated interventions [6], provision
of medical knowledge, validation of patient experiences,
strong interpersonal skills and provider availability [4].
The use of an interprofessional (IP) team approach
may further facilitate the process of SDM. Diabetes care
occurs in the context of IP care [7], which has been shown
to improve clinical outcomes [8–10]. Furthermore, IP care
may facilitate uptake of SDM [11]. Hence, an IP approach
to SDM is the process whereby two or more health care
professionals are involved in making the decision with the
patient [12]. This approach may occur synchronously, but
it more often occurs asynchronously and therefore re-
quires a shared framework with a common understanding.
Achieving a common understanding of the essential ele-
ments of the SDM process among the IP team, as well as
recognizing the influence of the various individuals on
this process, will improve success in reaching a shared
decision.
SDM can be facilitated by the use of patient decision
aids (PtDAs) [6, 13, 14], as they help frame the decision
to be made. The authors of a 2014 Cochrane review of
PtDAs identified 115 studies and found that PtDAs im-
proved decision quality and process and that, when used
within the consultation with the health care practitioner,
patients were more likely to achieve SDM with theirpractitioner compared with patients using a PtDA on
their own [6, 15]. We identified six PtDAs focused on
diabetes, one evaluated with a prospective observational
study [16], four evaluated through RCTs [15, 17–22] and
one RCT protocol [23]. These PtDAs included a goal-
setting intervention [16, 22], Diabetes Medication Choice
[17], Statin Choice [15, 18, 19, 21] and a metabolic control
aid [20]. These were studied in specialty clinics [15, 16, 18,
19, 23], in primary care settings [17, 21, 22] and among
the general public [20]. Whereas knowledge, risk percep-
tion, satisfaction, decision-making participation, trust, de-
cisional conflict and documented goals improved, there
was no impact on diabetes empowerment or clinical out-
comes. The effect on medication adherence was mixed. In
one before-after study and one RCT, researchers have
examined the impact of goal-setting decision aids [16, 22].
In the first study [16], the intervention (consisting of a
28-page patient workbook, a 2-hour patient education
session and two 2-hour medical resident seminars) was
delivered in a primary care clinic and resulted in in-
creased knowledge (P = 0.001), number of documented
diabetes goals (pre: 0.67 goals; post: 1.09 goals; P< 0.001),
but no improvement in glycemic control, weight or dia-
betes empowerment score were noted. In the second
study, the investigators examined the impact of another
goal-setting and SDM aid in 344 patients with uncom-
plicated type 2 diabetes in 18 Dutch primary care practices
[22]. This electronic medical record–generated decision
aid presented to patients their individually calculated risks
of vascular disease based on the patients’ cardiometabolic
profile. No difference was found in patient empowerment
for setting and achieving goals. These interventions did
not specifically address patient-important priorities and
preferences. In addition, effectiveness may be optimized
by providing a point-of-care tool for use at the time of
consultation and a provider-specific tool, emphasizing
longitudinal use, and more explicitly integrating the IP
team.
We hypothesize that a multicomponent PtDA toolkit
(patient-directed, provider-directed and point-of-care tools)
that helps to individualize care priorities and incorporates
an IP approach to SDM may help to implement complex
guideline recommendations for patients with type 1 or type
2 diabetes and other comorbidities and may also improve
the decision-making process and quality as well as patient-
centered outcomes. We elected to examine this population,
given the added relevance of a goal-setting aid in patients
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goal of this study is to assess intervention fidelity (i.e., if,
how and when the toolkit is actually used in clinical care)
as well as the feasibility of scaling up the intervention and
study to a larger RCT to determine the efficacy and effect-
iveness of the SDM tool to improve clinical outcomes.
Methods/Design
Study overview
In this protocol, we describe the fifth and sixth phases of
a multiphase program of research described elsewhere [1].
We adopted the Knowledge-to-Action Framework and
engaged knowledge users throughout the process by in-
cluding patients, primary care providers and other stake-
holders as members of the research team to optimize
implementation [24]. Briefly, this program consists of six
phases, with the first four being feasibility testing (phase 1),
IP-SDM toolkit development (phase 2), heuristic evaluation
(phase 3) and usability testing (phase 4). Throughout the
development process, the toolkit will be refined iteratively
based on findings of each phase. We will then conduct an
evaluation of the effectiveness of the PtDA toolkit by con-
ducting a two-step, pilot clustered RCT (phase 5), followed
by individual interviews (phase 6). We used the SPIRIT
checklist to report this protocol [25].
The initial aim of this phase is to assess intervention
fidelity and the feasibility of conducting a larger cluster
RCT to evaluate efficacy and effectiveness of the SDM
tool on clinical outcomes. The subsequent aim is to evalu-
ate the impact of the toolkit on a variety of patient-reported
outcomes, including patient decisional conflict, diabetes
distress, health-related quality of life and chronic care
delivery.
Phases 5 and 6: cluster randomized controlled trial and
individual interviews
Study design and objectives
An exploratory, two-step, parallel-group, clustered RCT
with a 1:1 allocation ratio will be conducted. We chose
to use a cluster RCT design to minimize contamination
of the control group and avoid biased estimates of effect
size [26].
The first step will be provider-directed (the toolkit will
be delivered only to the providers, including physicians,
nurses, dietitians and/or pharmacists); the second step
(which will occur 6 months later) will be provider- and
patient-directed (the toolkit will also be delivered to the
patient). The use of the two-step approach will allow us
to monitor uptake by population (provider or patient) as
well as barriers influencing uptake in our study setting.
Although patient-directed interventions improve health
behaviors and outcomes [27], optimal delivery of PtDA
(provider- or patient-directed strategy) is unclear. When
mailed to patients, viewing rates were as low as 25 %,whereas strategies dependent on providers failed, as the
providers did not see this as their role and were distracted
by competing demands [28]. We selected a 6-month inter-
val for each step to ensure sufficient time for health care
providers and patients to follow up, as well as to enable
adequate exposure to use of the PtDA to influence our
study outcomes.
Phase 5: cluster randomized controlled trial
Setting and participants Family practice groups will be
recruited from nine local health integration networks lo-
cated in southern Ontario, Canada. These networks were
designated by the Ontario Ministry of Health and Long-
Term Care to plan, integrate and fund local health ser-
vices, such as health service providers, community care
access centers, community health centers, community sup-
port services, hospitals and long-term care facilities [29].
We will exclude groups that do not have an IP staff that in-
cludes a nurse, dietitian or pharmacist or that do not have
an electronic medical record system capable of identifying
patients with diabetes. The research team will contact
medical directors of eligible practices to explain the project
and solicit their participation. Two to five physicians from
each family practice group will be invited to participate.
Using electronic medical records at each consenting
physician’s practice, the research coordinator will iden-
tify patients with diabetes and two other comorbidities
[heart disease (including ischemic, valvular, congestive,
arrhythmic and congenital disease), stroke, hypertension,
cancer survivor (excluding nonmelanoma skin cancer),
chronic lung disease, arthritis, inflammatory bowel disor-
ders and urinary incontinence]. Those patients who do
not speak English, have documented cognitive deficits, are
unable to give informed consent, have limited life ex-
pectancy (<1 year) or are not available for follow-up will
be excluded. In addition, patients who are involved in con-
current diabetes-related initiatives or who are seen by
resident physicians will be excluded, as this does not
represent usual clinical care. Patients who are seen by
resident physicians will be excluded because of limited
involvement of the IP team, smaller patient practices
and limited resident availability owing to other training
needs.
Intervention arm PtDA development has been described
previously [1]. We developed an IP-SDM toolkit based
on the IP-SDM framework [30] and according to the
International Patient Decision Aids Standards criteria
[31]. The IP-SDM framework consists of seven steps in
SDM and considers the role of the patient, the family
and the health care team. These steps are (1) assessment
of decision to be made, (2) information exchange, (3)
values and preferences, (4) feasibility, (5) preferred choice,
(6) actual choice and (7) implementation [12, 32]. Actions
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cardiometabolic and psychosocial profile, determining
the patient’s general priorities for care, eliciting the pa-
tient’s diabetes-specific goals and outcomes, outlining
diabetes-specific therapies and their benefits and risks
and synthesizing these items and the patient’s selected
strategies into an action plan. The tool ranks goals and
strategies based on the evidence underlying the clinical
practice guidelines (CPG) recommendation as well as
patient values. Use of the IP-SDM toolkit within the
team will be contextualized to each site and based on the
usual roles, responsibilities and processes of care of the
health care team. The IP-SDM toolkit is in English, and
the patient-directed components target a grade 8 literacy
level (i.e., readability score) [31].
At study start, the toolkit, consisting of the online de-
cision aid, a one-page provider enabler (a laminated sheet
summarizing the purpose and flow of the decision aid
with step-by-step instructions and accompanying screen-
shots), a similar one-page patient enabler and brief train-
ing videos for both providers and patients will be
distributed by the research coordinator to each of the
health care providers in practices randomized to the
toolkit; this constitutes the provider-directed intervention
phase (step 1). After 6 months, a link to the PtDA will be
emailed to eligible patients; this constitutes the provider- and
patient-directed phase (step 2). On the basis of the final re-
sults of phases 1–4 (ongoing at time of protocol publica-
tion), we will incorporate other strategies to overcome
barriers to use and optimize implementation before
trial initiation.
Control arm At study start, a paper copy of the executive
summary of the Canadian Diabetes Association (CDA)
clinical practice guidelines and a postcard outlining online
clinical information resources will be distributed to each
of the health care providers in practices randomized
to the control group. After 6 months, copies of a CDA
patient education pamphlet regarding diabetes self-
management and a postcard outlining online additional
patient resources will be mailed to eligible patients. These
provider- and patient-directed guideline dissemination
tools (not incorporating SDM) have been launched widely
and are also publicly accessible on the CDA guidelines
website (guidelines.diabetes.ca).
Outcome measures Initial aim: The feasibility of con-
ducting a larger cluster RCT to improve diabetes-related
clinical outcomes will be assessed by recruitment and
retention of study participants through evaluating study
procedures and processes, including recruitment response
rate and number of eligible patients, time required to
recruit adequate sample size, questionnaire response rate,
willingness of participants to be randomized and willingnessof clinicians to recruit patients. We will deem the study
feasible if we are able to complete recruitment within a
12-month period and attain a questionnaire response
rate of 75 % or higher for completion of at least 75 % of
the patient questionnaires. This will inform whether we
will proceed with a larger trial or if we need to modify
study processes before going forward. Intervention
fidelity will be assessed by patterns of use of the inter-
vention through examination of website use statistics,
such as frequency and duration of specific components
of the intervention and patterns of use over time.
Subsequent aim: The primary outcome is decisional
conflict [33]. Secondary outcomes are diabetes distress [34],
health-related quality of life [35], chronic illness care [36]
and intention to engage in IP-SDM [37]. These outcomes
will be assessed by using well-validated, patient-completed
questionnaires at baseline, 6 months and 12 months
through online surveys (Table 1). These questionnaires
take approximately 15–20 minutes to complete. These
outcomes were selected because they are direct measures
of knowledge use by patients that will allow us to better
understand mediating variables of knowledge use, such
as patient activation, goal-setting, problem-solving and
decision-making support. Decisional conflict was chosen
to allow us to assess the impact of our PtDA on the
quality of the decision-making process, an important
first measure of the effectiveness of a PtDA [38] and
the SDM process [39]. Diabetes distress was selected as
a holistic and patient-centered measure of knowledge
use that uniquely acknowledges patient prioritization of
health care goals [40, 41]. Health-related quality of life
was chosen to complement diabetes-specific quality of
life to assess general health, given the nature of the
PtDA and complex patient population selected [42]. Pa-
tient perception of chronic illness care was selected to
assess key elements of the chronic care model namely,
patient activation, goal-setting, problem-solving and/or
contextual counseling, delivery system design and/or
decision-making support and follow-up and/or coord-
ination [36]. Providers’ intention to engage in SDM will
be assessed with an 11-item questionnaire based on the
theory of planned behavior [37]. Surrogate clinical out-
comes (e.g., hemoglobin A1C level) were not chosen, owing
to their limited relevance to the individualized nature of
our toolkit.
Sample size calculation On the basis of a previous study
in which the decisional conflict scale [43] was used, a
clinically meaningful effect size of 0.4 with a standard
deviation of 0.6, α of 0.05 and β of 0.10 will be employed
for sample size calculations. With at least 40 patients
per physician, a 50 % participation rate and an antici-
pated attrition rate of 25 %, we expect about 15 patients
per site to participate. Previous data have shown that the
Table 1 Schedule of enrollment, interventions and assessments
Study period
Enrollment Allocation Postallocation Closeout













Providers: age, sex, duration in practice, practice load, remuneration plan,
academic or community practice, rural or urban practice, solo or group practice
Patients: age, sex, ethnicity, age at diagnosis, comorbidities, smoking status,
educational attainment, annual income
Outcome variables
Logs of all study processes to assess recruitment and retention
Website use statistics X
Decisional conflict, diabetes distress, health-related quality of life, chronic illness
care, intention to engage in IP-SDM
X X X
Qualitative interviews X
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decisional conflict for patients with diabetes clustered
within primary care physicians [44]. Therefore, the sample
size required, accounting for clustering, is 56 patients per
intervention and control group, or 4 sites per intervention
and control group.Randomization Practices will be simultaneously ran-
domized and allocated by a biostatistician to either the
intervention or control arm using computer-generated
randomization in a 1:1 ratio. A biostatistician will take
the list of all eligible patients from each cluster and gen-
erate by computer a random order list. Assuming a 50 %
response rate to recruitment, we will select the first 40
patients from this random order list and invite them to
participate. If we are not able to recruit 20 patients from
this initial group of 40, we will send out additional invi-
tations to the subsequent participants from this random
order list.Risk of bias After assignment, investigators, research
coordinators or trial participants will no longer be blinded
to group allocation, owing to the nature of the interven-
tion. Each practice will be given a code, and the biostatisti-
cian will analyze the data blindly. Codes will be accessed
after analysis is completed.Data collection Initial aim: The research team will keep
detailed records prospectively of recruitment methods
employed, using a log for each level of recruitment,
comprising family practice groups, physicians and patients
(Additional file 1). To assess intervention fidelity, we will
collect website use statistics by analyzing server logs upon
study completion (Additional file 2).
Subsequent aim: At trial entry, sociodemographic infor-
mation will be obtained (for providers: age, sex, duration
in practice, practice load, remuneration plan, academic or
community practice, rural or urban practice, solo or group
practice; for patients: age, sex, ethnicity, age at diagnosis,
comorbidities, smoking status, educational attainment, an-
nual income). Data on outcomes will be collected by using
participant-completed questionnaires (Additional file 3)
submitted (either online or mailed according to patient
preference) at 6-month intervals and at study completion,
corresponding to intervention steps 1 and 2 for a total of
3 data points over a 12-month period. Participants will be
reminded twice by email or telephone at 2-week intervals
to complete the questionnaires. Data will be stored on the
secure, password-protected institutional server. All hard-
copy data will be stored in a locked and secured filing
cabinet at the research institute.Analysis Initial aim: We will conduct basic frequency and
descriptive statistical analysis of our retention, recruitment
and use objectives for intervention fidelity and feasibility.
Subsequent aim: We hypothesize that patients in the
intervention arm will have reduced decisional conflict.
We hypothesize they will have reduced diabetes distress
and improved quality of life and chronic care delivery.
Analysis will be done by intention to treat. The analysis
to test this hypothesis will be carried out using multilevel
hierarchical models (generalized estimating equations for
binary outcomes and linear mixed-effects models for con-
tinuous outcomes) to account for the clustered nature of
the data. The group assignment will be a physician-level
variable. The robustness of the primary analysis to missing
data will be assessed by imputing best and worst case
scenarios for missing data. We will also assess the impact
of sociodemographic variables on these outcomes, as the
literature demonstrates that not all patients and providers
want SDM [45–47]. In addition, to facilitate better plan-
ning for a subsequent larger trial, standard deviations of
our primary outcome measures will be used to more pre-
cisely estimate sample size for the future.
Data monitoring We did not create a data monitoring
committee, given the pilot nature of this study, low risk
to trial participants and assessment of less serious outcomes.
We will keep a prospective log of adverse events and other
unintended effects.
Phase 6: individual interviews
Participants Individual interviews will be conducted
with patients, their family members and their health care
providers following completion of the trial. We will use
purposive sampling to recruit participants with a range
of experiences and characteristics [48] from among the
broader pool of trial participants who were randomized
to the intervention arm. Fifteen to twenty interviews in
total are anticipated to reach theoretical saturation [48].
Data collection To assess intervention fidelity, we will
assess toolkit use and the manner with which it was
used (e.g., which components, which individuals). To as-
sess the feasibility of scaling up to a larger cluster RCT,
we will evaluate the acceptability of the toolkit and inter-
vention, reasons for use and nonuse, and barriers to and
facilitators of use.
We will use a semistructured interview guide to elicit
participants’ views regarding the IP-SDM process and inter-
vention use. The details will include acceptability, usability,
strengths and weaknesses of the intervention; facilitators of
and barriers to its use, user satisfaction; and sustainability
of its use (Additional file 4). We will make the intervention
available during each interview.
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scribed verbatim [49]. Transcripts will be analyzed induct-
ively using a constant comparative approach to identify
emergent themes [50]. Coding will be conducted inde-
pendently by two team members with expertise in qualita-
tive research methods. The coding framework will be
developed and then iteratively tested and refined with sub-
sequent interviews [50]. NVivo software (version 9; QSR
International, Doncaster, Australiawill be used to assist
with data management and retrieval.
Research ethics
The study was approved by the research ethics boards
(REBs) of St. Michael’s Hospital (reference number 13-
014C), Sunnybrook Health Sciences Health Center (ref-
erence number 345-2013), Women’s College Hospital
(reference number 2013-0058), Toronto East General
Hospital (reference number 609-1410-Mis-245), North York
General Hospital (reference number 13-0265), Southlake
Regional Health Center (reference number 0055-1314) and
Markham-Stouffville Hospital. Protocol amendments will
be submitted to the relevant REB before trial participants are
informed, and they will be registered at ClinicalTrials.gov.
Eligible patients will be mailed an information letter
(Additional file 5), then called the following week. If
the patients are interested in participating in the study,
they will be asked to complete an online consent form.
We will obtain informed consent from each participant.
To protect confidentiality, study identification numbers
will be used on study surveys. The master log that links
study identification numbers to any personal information
will be kept separately. Research team members will have
access to the final trial dataset. We do not anticipate any
harm to be caused by trial participation.
Dissemination
Trial results will be communicated to study participants
by letter, to each study site by presentation and to academic
audiences through publications and conference presen-
tations. International Committee of Medical Journal Edi-
tors authorship guidelines will be followed.
Discussion
Diabetes is a complex chronic disease, and its manage-
ment is further complicated by other common comorbidi-
ties. Adopting a patient-centered SDM approach whereby
patients, supported by their health care team, set goals
and management priorities has the potential to improve
the delivery of care and patient-important outcomes, such
as quality of life, as well as the uptake of patient-relevant
guideline recommendations. Our objective is to pilot
and evaluate a diabetes-focused SDM and priority-setting
PtDA in IP primary care practices.Effective implementation of SDM and PtDAs into clin-
ical practice requires practical delivery mechanisms [51, 52].
We will identify barriers to and employ facilitators of
implementation identified in the literature [3–6] and in
earlier phases of this project. We will also assess interven-
tion fidelity and use in our feasibility study and interviews.
The study’s strengths include its randomized design and
clustered nature, use of validated patient-important out-
comes, knowledge-user engagement (primary care pro-
viders, people with diabetes), varied team expertise (SDM,
knowledge translation, information technology, primary
care diabetes, and qualitative and quantitative research
methods), dual coding of interview transcripts and tri-
angulation of qualitative and quantitative results [48, 50, 53].
The limitations and challenges of this study potentially
include volunteer bias and inadequate recruitment. We will
assess volunteer bias by comparing sociodemographic
characteristics of participants and nonparticipants, which
will further inform recruitment in a subsequent, larger, de-
finitive trial. We hope to optimize successful recruitment
and implementation with our combined knowledge user-
researcher team.
IP-SDM has not been taken up extensively in clinical
care, but it has the capacity to help focus the care of
patients with multiple comorbidities in the face of an
overwhelming volume of recommendations. By assessing
intervention use and fidelity, barriers to and facilitators
of implementation, and patient-important outcomes, this
study will contribute to the understanding of its role in
clinical care in our evolving, complex population, and it
has the potential to impact chronic care delivery and out-
comes that are of relevance to patients with multiple
comorbidities.Trial status
Recruitment of study sites and participants is ongoingAdditional files
Additional file 1: Recruitment log.
Additional file 2: Website use statistics.
Additional file 3: Description of primary and secondary outcome
scales.
Additional file 4: Semistructured Interview Guide.
Additional file 5: Information and consent form.Abbreviations
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